US FDA Nod Merck's Keytruda Plus Carboplatin And Paclitaxel

Merck reported that the US Food and Drug Administration (FDA) has approved Keytruda, the company's anti-PD-1 medication, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients...

LSL Pharma Group Concludes the Acquisition of Virage Sante

LSL PHARMA GROUP INC., a Canadian based pharmaceutical firm, is pleased to declare the acquisition of Virage Santé, a firm, that specializes in the production and distribution of natural health products (NHPs). LSL Pharma's contract development...

Cipla To Fund Additional 3 Million Euros in Ethris

Cipla, a leading global pharmaceutical firm, announced that it will make an additional investment of 3 million euros in Ethris, a company based in Germany that is developing potential treatments for respiratory diseases using its own mRNA...

Aprea Therapeutics Commences Patient Dosing in Phase 1 Trial

Aprea Therapeutics, Inc., a biopharmaceutical firm that specializes in precision oncology through synthetic lethality, declared that the first patient has been dosed in the ACESOT-1051 phase 1 study. The study evaluates which is evaluating the...

MGI Tech and SeqOne Join Hands To Advance Complete Genomic Analysis

MGI, an organization focused on building center instruments and advances that drive development in life science, declared partnership with SeqOne, a leading provider of artificial intelligence driven genomic choice support software...

AstraZeneca's Imfinzi Plus Chemotherapy Receives US FDA Nod

AstraZeneca's Imfinzi (durvalumab) has been approved as a treatment for adult patients with mismatch repair deficient (dMMR) primary, advanced, or recurrent endometrial cancer, in the United States. This can be followed by Imfinzi...

© 2024 India Pharma Outlook. All Rights Reserved.